Is this a habit forming medicine
Rebate Reports for applicable calendar quarters in calendar years 2023 and 2024
Supplement (176): 852, table of contents
However, because Leqembi is subject to the NCD for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease under coverage with evidence development (CED), [241] and because Leqembi was initially marketed and sold under accelerated approval, Leqembi coverage under Part B required the product to be furnished in a randomized controlled trial (RCT) conducted under an investigational new drug (IND) application
The incorporation of higher data completeness criteria thresholds in future years ensures a more accurate assessment of a MIPS eligible clinician's performance on quality measures and prevents selection bias to the extent possible (81 FR 77120, 82 FR 53632, 83 FR 59758, 86 FR 65436, 87 FR 70049, and 88 FR 79334)